Abstract:Therapeutic antibodies have become one of the most influential therapeutics in modern medicine to fight against infectious pathogens, cancer, and many other diseases. However, experimental screening for highly efficacious targeting antibodies is labor-intensive and of high cost, which is exacerbated by evolving antigen targets under selective pressure such as fast-mutating viral variants. As a proof-of-concept, we developed a machine learning-assisted antibody generation pipeline AbGen that greatly accelerates the screening and re-design of immunoglobulins G (IgGs) against a broad spectrum of SARS-CoV-2 coronavirus variant strains. Our AbGen centers around a novel antibody language model (AbLM) that is pretrained on 12 million generic protein domain sequences and fine-tuned on 4,000+ paired VH-VL sequences, with IgG-specific CDR-masking and VH-VL cross-attention. AbLM provides a latent space of IgG sequence embeddings for AbGen, including (a) landscapes of IgGs' activities in neutralizing the wild-type virus are analyzed through structure prediction for IgG and IgG-antigen (viral protein spike's receptor binding domain, RBD) interactions; and (b) landscapes of IgGs' susceptibility in neutralizing variant viruses are predicted through Gaussian process regression, despite that as few as 14 clinical antibodies' responses to variants of concern are available. The AbGen pipeline was applied to over 1300 IgG sequences we collected from RBD-binding B cells of convalescent patients. With experimental validations, AbGen efficiently prioritized IgG candidates against a broad spectrum of viral variants (wildtype, Delta, and Omicron), preventing the infection of host cells in vitro and hACE2 transgenic mice in vivo. Compared to other existing protein language models that require 10-100 times more model parameters, AbLM improved the precision from around 50% to 75% to predict IgGs with low variant susceptibility. Furthermore, AbGen enables structure-based computational protein redesign for selected IgG clones with single amino acid substitutions at the RBD-binding interface that doubled the IgG blockade efficacy for one of the severe, therapy-resistant strains - Delta (B.1.617). Our work expedites applications of artificial intelligence in antibody screen and re-design combining data-driven protein language models and Kriging for antibody sequence analysis and activity prediction, in synergy with physics-driven protein docking and design for antibody-antigen interface analyses and functional optimization.

Development of a new genotype–phenotype linked antibody screening system

High titer expression of antibodies using linear expression cassettes for early-stage functional screening

High-throughput antibody screening with high-quality factor nanophotonics and bioprinting

Automated high-throughput purification of antibody fragments to facilitate evaluation in functional and kinetic based assays.

Preparation of monoclonal antibodies against Yamagata-lineage influenza B virus hemagglutinin protein and establishment of a dual antibody sandwich ELISA detection method

Expression and characterization of recombinant antibodies against H7 subtype avian influenza virus and their diagnostic potential

A rapid cell-free expression and screening platform for antibody discovery

Genotyped functional screening of soluble Fab clones enables in-depth analysis of mutation effects

Function-based High-Throughput Screening for Antibody Antagonists and Agonists Against G Protein-Coupled Receptors

Developing a High-Throughput Screening-Based Purification Method for Bispecific Antibodies

A novel selection strategy for antibody producing hybridoma cells based on a new transgenic fusion cell line

High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics

Generation and Screening of Antigen-Specific Nanobodies from Mammalian Cells Expressing the BCR Repertoire Library Using Droplet-Based Microfluidics

Developing a workflow for the isolation of hybridoma cells producing fully human antigen-specific antibodies using a surface IgG detection method

Novel antibody language model accelerates IgG screening and design for broad-spectrum antiviral therapy

Rapid generation of high-quality recombinant antibodies using an Expi293F expression system for a 17 β-estradiol immunoassay

Rapid discovery of monoclonal antibodies by microfluidics-enabled FACS of single pathogen-specific antibody-secreting cells

Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities

High throughput monoclonal antibody generation by immunizing multiple antigens

A Combinatory Antibody–Antigen Microarray Assay for High-Content Screening of Single-Chain Fragment Variable Clones from Recombinant Libraries

Development of functional antibodies against influenza B virus by activation-induced cytidine deaminase in hybridoma cells